NZ603774A - Desazadesferrothiocin analogues as metal chelation agents - Google Patents

Desazadesferrothiocin analogues as metal chelation agents

Info

Publication number
NZ603774A
NZ603774A NZ603774A NZ60377411A NZ603774A NZ 603774 A NZ603774 A NZ 603774A NZ 603774 A NZ603774 A NZ 603774A NZ 60377411 A NZ60377411 A NZ 60377411A NZ 603774 A NZ603774 A NZ 603774A
Authority
NZ
New Zealand
Prior art keywords
desazadesferrothiocin
metal chelation
analogues
chelation agents
anemia
Prior art date
Application number
NZ603774A
Other languages
English (en)
Inventor
James W Malecha
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of NZ603774A publication Critical patent/NZ603774A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NZ603774A 2010-05-04 2011-05-04 Desazadesferrothiocin analogues as metal chelation agents NZ603774A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33113810P 2010-05-04 2010-05-04
PCT/US2011/035211 WO2011140232A2 (en) 2010-05-04 2011-05-04 Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Publications (1)

Publication Number Publication Date
NZ603774A true NZ603774A (en) 2014-11-28

Family

ID=44902334

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603774A NZ603774A (en) 2010-05-04 2011-05-04 Desazadesferrothiocin analogues as metal chelation agents

Country Status (9)

Country Link
US (3) US9045440B2 (https=)
EP (1) EP2566854A4 (https=)
JP (1) JP2013525495A (https=)
CN (1) CN103038223A (https=)
AU (1) AU2011248158A1 (https=)
BR (1) BR112012028321A2 (https=)
CA (1) CA2798082A1 (https=)
NZ (1) NZ603774A (https=)
WO (1) WO2011140232A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
JP5439193B2 (ja) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシンポリエーテル類似体
US8063227B2 (en) * 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) * 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
TW201338777A (zh) 2011-12-09 2013-10-01 Ferrokin Biosciences Inc 用於治療金屬過載之經口調配物
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
WO2014089482A1 (en) * 2012-12-07 2014-06-12 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
WO2014122664A1 (en) * 2013-02-11 2014-08-14 Yeda Research And Development Co. Ltd. Lanthanide clusters and methods of use thereof
EP2970162A1 (en) 2013-03-15 2016-01-20 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
CA2930966A1 (en) * 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
EP3288557A4 (en) * 2015-04-27 2018-11-07 University of Florida Research Foundation, Inc. Metabolically programmed metal chelators and uses thereof
KR20230004944A (ko) * 2016-08-05 2023-01-06 아브페로 파마슈티칼스, 인크. 금속-매개 상태를 치료하기 위한 투여 요법
TWI791362B (zh) 2021-12-27 2023-02-01 財團法人工業技術研究院 有機金屬錯合物、包含其之觸媒組合物、以及聚烯烴的製備方法
CN118561711B (zh) * 2024-07-31 2024-11-22 爱斯特（成都）生物制药股份有限公司 一种制备n-[8-(2-羟基苯甲酰基)氨基]辛酸及其盐的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3002989A1 (de) 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
US6251927B1 (en) * 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
US20030022923A1 (en) * 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
AT500490A1 (de) 2001-10-16 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte
WO2004017959A2 (en) 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
AU2003268706A1 (en) 2002-10-01 2004-04-23 Kaneka Corporation PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-SUBSTITUTED CYSTEINE OR SALT THEREOF, INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING THE SAME
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
JP2007505044A (ja) * 2003-09-09 2007-03-08 ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド ポリアミン−金属キレーター接合体
JP2005289890A (ja) * 2004-03-31 2005-10-20 Mitsubishi Pharma Corp ムスカリン性アセチルコリン受容体結合阻害剤
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
US20080093812A1 (en) 2006-05-22 2008-04-24 Ronald Reed Rolling baggage wheels and method for manufacturing the same
US20080138440A1 (en) 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
US20100137346A1 (en) 2006-12-12 2010-06-03 University Of Florida Research Foundation, Inc. Desferrithiocin analogue actinide decorporation agents
JP5439193B2 (ja) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシンポリエーテル類似体
US8063227B2 (en) 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
CN101928281A (zh) * 2009-06-24 2010-12-29 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
BR112012001761A2 (pt) * 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
US20120184586A1 (en) 2009-08-25 2012-07-19 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof

Also Published As

Publication number Publication date
CN103038223A (zh) 2013-04-10
WO2011140232A3 (en) 2012-02-23
EP2566854A2 (en) 2013-03-13
BR112012028321A2 (pt) 2017-03-21
US20130053387A1 (en) 2013-02-28
JP2013525495A (ja) 2013-06-20
WO2011140232A2 (en) 2011-11-10
CA2798082A1 (en) 2011-11-10
US20110275636A1 (en) 2011-11-10
EP2566854A4 (en) 2013-11-06
US20150259306A1 (en) 2015-09-17
AU2011248158A1 (en) 2012-12-20
US9045440B2 (en) 2015-06-02

Similar Documents

Publication Publication Date Title
NZ603774A (en) Desazadesferrothiocin analogues as metal chelation agents
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
NZ590302A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
MX2010002244A (es) Nuevos fungicidas.
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
PH12017500755A1 (en) 2 substituted cephem compounds
NZ597517A (en) 5-fluoropyrimidinone derivatives
MY152114A (en) Novel pyrazole-4-n-alkoxycarboxamides as microbiocides
PH12014502169A1 (en) N-cyclylamides as nematicides
MX339992B (es) Piridin-2-amidas utiles como agonistas canabinoides 2 (cb2).
NZ608285A (en) Manufacturing process for pyrimidine derivatives
MY176680A (en) Cyclic amides as metap-2 inhibitors
MX352975B (es) Piridina y derivados de pirazina.
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX345127B (es) Derivados de tiazol.
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
GEP201706741B (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2015007053A (es) Compuestos dimericos.
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
MX2011007266A (es) Microbiocidas nuevos.
PH12015501400A1 (en) Herbicidal composition comprising a cornexistin
MX2009010959A (es) Derivados de piridazina, piridina y pirano como agonistas gpbar1.
MX2012007539A (es) Derivados de hidroximoil-tetrazol fungicidas.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: FERROKIN BIOSCIENCES, INC., US

Effective date: 20140925

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2016 BY COMPUTER PACKAGES INC

Effective date: 20150418

LAPS Patent lapsed